BMJ Open

Comparison of standard prophylactic, intermediate prophylactic and therapeutic anticoagulation in patients with severe COVID-19: protocol for the ANTICOVID multicentre, parallel-group, open-label, randomised controlled trial

Vincent Labbe ,[1,2] Damien Contou,[3] Nicholas Heming,[4,5] Bruno Megarbane,[6] Hafid Ait-Oufella,[7] Florence Boissier,[8] Serge Carreira,[9] Alexandre Robert,[10,11] Emmanuel Vivier,[12] Mohamed Fejjal,[13] Denis Doyen,[14,15] Mehran Monchi,[16] Sebastien Preau,[17] Elise Noel-Savina,[18] Bertrand Souweine,[19] Noémie Zucman,[20,21] Santiago Alberto Picos,[22] Martin Dres ,[23] William Juguet,[24] Eric Mariotte,[25] Jean-François Timsit,[26] Matthieu Turpin,[1] Keyvan Razazi,[2,27] Ségolène Gendreau,[2,27] Samia Baloul,[28] Guillaume Voiriot ,[1,2] Muriel Fartoukh,[1,2] Etienne Audureau,[28] Armand Mekontso Dessap [2,27]

To cite: Labbe V, Contou D, Heming N, *et al*. Comparison of standard prophylactic, intermediate prophylactic and therapeutic anticoagulation in patients with severe COVID-19: protocol for the ANTICOVID multicentre, parallel-group, open-label, randomised controlled trial. *BMJ Open* 2022;**12**:e059383. doi:10.1136/bmjopen-2021-059383

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2021-059383).

Received 20 November 2021
Accepted 14 February 2022

For numbered affiliations see end of article.

Correspondence to
Dr Vincent Labbe;
vincent.labbe@aphp.fr

ABSTRACT

Introduction COVID-19 induces venous, arterial and microvascular thrombosis, involving several pathophysiological processes. In patients with severe COVID-19 without macrovascular thrombosis, escalating into high-dose prophylactic anticoagulation (HD-PA) or therapeutic anticoagulation (TA) could be beneficial in limiting the extension of microvascular thrombosis and forestalling the evolution of lung and multiorgan microcirculatory dysfunction. In the absence of data from randomised trials, clinical practice varies widely.

Methods and analysis This is a French multicentre, parallel-group, open-label, randomised controlled superiority trial to compare the efficacy and safety of three anticoagulation strategies in patients with COVID-19. Patients with oxygen-treated COVID-19 showing no pulmonary artery thrombosis on computed tomography with pulmonary angiogram will be randomised to receive either low-dose PA, HD-PA or TA for 14 days. Patients attaining the extremes of weight and those with severe renal failure will not be included. We will recruit 353 patients. Patients will be randomised on a 1:1:1 basis, and stratified by centre, use of invasive mechanical ventilation, D-dimer levels and body mass index. The primary endpoint is a hierarchical criterion at day 28 including all-cause mortality, followed by the time to clinical improvement defined as the time from randomisation to an improvement of at least two points on the ordinal clinical scale. Secondary outcomes include thrombotic and major bleeding events at day 28, individual components of the primary endpoint, number of oxygen-free, ventilator-free and vasopressor-free days at day 28, D-dimer and sepsis-induced coagulopathy score at day 7, intensive care unit and hospital stay at day 28 and day 90, and all-cause death and quality of life at day 90.

Ethics and dissemination The study has been approved by an ethical committee (Ethics Committee, Ile de France VII, Paris, France; reference 2020-A03531-38). Patients will be included after obtaining their signed informed consent. The results will be submitted for publication in peer-reviewed journals.

Trial registration number NCT04808882.

Strengths and limitations of this study

- This randomised controlled trial may contribute to establish solid recommendations with a high level of evidence on the best anticoagulation strategy to limit the extension of microvascular thrombosis and to forestall the evolution of lung and multiorgan microcirculatory dysfunction in patients with severe COVID-19 without initial macrovascular thrombosis.
- Eligibility criteria differ from those retained by previous published studies on anticoagulation strategies in patients with COVID-19 given the systematic pre-randomisation screening for macrothrombosis and the exclusion of obese and renal failure patients to minimise baseline bleeding risk.
- One limitation of the trial is that it is not blinded.

INTRODUCTION

Background and rationale

COVID-19, a respiratory viral infection caused by SARS-CoV-2, may predispose patients to thrombotic complication[1] incurred by a combination of intense inflammation, platelet activation and endothelial

dysfunction leading to respiratory distress and high mortality.[2–4]

The incidence of macrovascular thrombotic events varies from 10% to 30% in COVID-19 hospitalised patients depending on the type of thrombosis, arterial or venous, and the severity of the illness.[2–4] Based on observational data of patients receiving routine low-dose prophylactic anticoagulation (LD-PA), several institutions released guidance statements recommending escalated anticoagulant doses to prevent macrovascular thrombotic events.[5 6] In these recommendations, high-dose PA (HD-PA) and therapeutic anticoagulation (TA) can be employed either empirically or based on various criteria like body mass index or D-dimer concentration.[5–7] However, other conflicting recommendations challenge this approach.[6 8]

Microvascular thrombotic events are another major concern in COVID-19 patients. A large review screened the autopsy findings of COVID-19-related deaths and reported the presence of microthrombi in small pulmonary vessels.[9] COVID-19-induced endothelitis and coagulopathy across vascular beds of different organs precipitate widespread microvascular thrombosis.[2 10 11] Thus, in critically ill COVID-19 patients without initial macrovascular thrombotic event, HD-PA or TA could be beneficial in limiting the extension of microvascular thrombosis and forestalling lung and multiorgan microcirculatory dysfunction.

To date, no randomised clinical trial has evaluated the best anticoagulation strategy in patients with severe COVID-19, in whom an initial macrovascular thrombotic event is systematically excluded. It seems important to rationalise and compare anticoagulation strategies in this population.

Hypothesis

Our hypotheses are formulated in patients who have severe COVID-19 pneumonia and are macrovascular-thrombosis free to assess: (1) First, that TA and HD-PA strategies mitigate microthrombosis, and each thwarts COVID-19 progression to respiratory failure and multiorgan dysfunction, thus decreases mortality and disease duration, as compared with LD-PA; (2) second, that TA outperforms HD-PA in this setting.

Objectives

Primary objective

The main objective is to compare the efficacy of the three strategies (LD- PA, HD-PA and TA) in reducing mortality and time to clinical improvement.

Secondary objectives

The secondary objectives are to compare the benefits and risks of the three strategies (LD-PA, HD-PA and TA) in terms of: (1) mortality, morbidity and organ dysfunction; (2) thrombotic events, bleeding events and net clinical benefit.

Ancillary study

An ancillary study will assess clinical and biological characteristics of severe COVID-19 pneumonia with or without pulmonary embolism to establish a scoring system for COVID-19-related pulmonary embolism diagnosis.

METHODS AND ANALYSIS

Trial design

This is a French multicentre, parallel-group, open-label, randomised controlled superiority trial to compare the efficacy and safety of three anticoagulation strategies (LD- PA, HD-PA and TA) in patients with COVID-19 pneumonia. The trial protocol follows the Standard Protocol Items: Recommendations for Interventional Trial (SPIRIT) reporting guidelines.

Study setting

The study will be conducted in 31 units (23 intensive care units (ICUs) and 8 conventional hospital wards) in 23 hospitals in France (list of the study sites in online supplemental appendix A).

Eligibility criteria

Inclusion criteria

Adult patients (age ≥18 years) admitted to hospital will be eligible as soon as they meet all of the following criteria:

- Severe COVID-19 pneumonia, defined by: (1) new pulmonary parenchymal infiltrate and (2) positive Reverse Transcription (RT)-PCR (either upper or lower respiratory tract) for SARS-CoV-2 and (3) WHO ordinal scale ≥5.[12];
- Provide written informed consent as per the French law (patient, next of kin or differed consent if an emergency case).

Non-inclusion criteria

Patients presenting any of the following criteria will not be included:

- Pregnant or breastfeeding women.
- Post partum (6 weeks).
- Attaining the extremes of body weight (<40 kg or >100 kg).
- Hospital admission of more than 72 hours (if the WHO ordinal scale is 5 at the time of inclusion) or ICU admission of more than 72 hours (if the WHO ordinal scale is 6 or more at time of inclusion).
- Clinical need for TA.
- Bleeding related to haemostasis disorders, acute clinically significant bleeding, presence of active gastrointestinal ulcer or any organic lesion with high risk for bleeding.
- Platelet count <50 x 10∧9/L.
- Within 15 days of recent surgery, within 24 hours of spinal or epidural anaesthesia;
- A history of intracranial haemorrhage, large acute ischaemic stroke, known intracranial malformation or neoplasm, acute infectious endocarditis.

- Severe renal failure (creatinine clearance <30 mL/min).
- Iodine allergy.
- Hypersensitivity to heparin or its derivatives including low-molecular-weight heparin (LMWH).
- A history of type II heparin-induced thrombocytopaenia (HIT).
- Chronic oxygen supplementation.
- Moribund patient or death expected from an underlying disease during the current admission.
- Patient deprived of liberty and persons subject to institutional psychiatric care.
- Patients under guardianship or curatorship.
- Participation in another interventional research on anticoagulation.

Intervention

All patients hospitalised with a positive RT-PCR (either upper or lower respiratory tract) for COVID-19 (SARS-CoV-2) in the participating centres will be systematically screened every day looking for inclusion and non-inclusion criteria. The number of patients who do not meet the inclusion criteria will be reported prospectively in a paper register by each of the participating centres. A patient identification number as well as the reason for non-inclusion will be noted (local register of non-inclusion in each of the concerned centres).

Inclusion (D0) is performed as soon as possible, within 72 hours of hospital admission (if the WHO ordinal scale is 5 at time of inclusion,[12]) or within 72 hours of ICU admission (if the WHO ordinal scale is 6 or more at time of inclusion[12]).

Chest CT with pulmonary angiogram (CTPA) should be performed within 72 hours before (or up to 24 hours after) inclusion; If CTPA is performed within 7 days of inclusion and the likelihood of pulmonary artery thrombosis is deemed unchanged by the clinician, the result of that CTPA might be considered at time of inclusion (figure 1).

- If the CTPA reveals pulmonary artery thrombosis, the patient will receive TA following current guidelines[13] and will not be randomised.
- If the CTPA does not show pulmonary artery thrombosis, the patient will be randomised to receive either LD-PA, HD-PA or TA for 14 days (or until hospital discharge or weaning of supplemental oxygen for 48 consecutive hours, whichever comes first). If the patient has no pulmonary artery thrombosis but presents clinical signs of deep venous thrombosis at inclusion, complete duplex ultrasound (CDUS) of the lower extremities will be performed.[14] If the CDUS demonstrates deep venous thrombosis, the patient will receive TA according to current guidelines and will not be randomised; if the CDUS is negative, the patient will be randomised.

LD-PA, HD-PA and TA will be initiated immediately in all patients after randomisation using LMWH, tinzaparin at a dose of 3500 IU/24 hours, 7000 IU/24 hours or 175 IU/kg/24 hours, respectively. If tinzaparin is not available, enoxaparin can be used at a dose of 4000 IU/24 hours, 4000 IU/12 hours and 100 IU/kg/12 hours, respectively.

In case renal failure (creatinine clearance <30 mL/min) happens after randomisation or if a patient needs



Figure 1 Experimental schema.

invasive, high bleeding risk procedure, better replace LMWH by a continuous intravenous infusion of unfractioned heparin as follows: (1) LD-PA: 100 IU/kg/24 hours; (2) HD-PA: 200 IU/kg/24 hours; (3) TA: 500 IU/kg/24 hours, adapted to the anti-Xa activity (target between 0.3 and 0.6 IU/mL) as per current guidelines.

After day 14, or hospital discharge, or in case TA is clinically indicated, or serious anticoagulation-related adverse event occurs, the trial anticoagulation strategy will be discontinued. Pursuing further anticoagulation treatment will be left at the discretion of the attending physicians.

In all groups, current recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone.[15]

Criteria and procedures of premature withdrawal of a participant from the study

In compliance with the conventional management of severe COVID-19 pneumonia, anticoagulation will be discontinued if one of the following happens:

- Major bleeding event (MBE) according to the International Society on Thrombosis and Haemostasis (ISTH) definition.
- Large acute ischaemic stroke.
- Skin necrosis at the injection site.
- Type II HIT.
- Allergic reaction.
- Hospital discharge prior to day 14.

The TA strategy will be temporarily interrupted if any of the following conditions arises before terminating the treatment period (14 days from randomisation); the study drug will be resumed at least 6 hours after the resolution of the anomaly:

- Clinical indication for TA.
- Indication for lumbar puncture, spinal or epidural anaesthesia.
- Indication for surgery.

Follow-up visits

The trial clinical examination is part of the daily practice. Parameters collected in the study are those usually collected during the management of patients with severe COVID-19 pneumonia. The trial follow-up visits are at day 7, day 28 and day 90.

If the patient is still hospitalised at day 28 and day 90, data will be collected from the patient's medical records with the possible assistance of a clinical research technician (CRT). If the patient is discharged:

- The CRT will collect the medical records from the clinical departments where the patient stayed; these will be analysed by the investigator who included the patient.
- The CRT will collect data on the patient's vital status and occurrence of serious adverse events during the follow-up period:
  - (If necessary) telephone the patient (three different attempts, days and times over 15 days).
  - (If necessary) telephone the physician in charge of the patient during the follow-up period.
  - (If necessary) telephone the patient's treating or referring physician(s).
  - (If necessary) contact the town hall of the patient's birthplace.

Endpoints

Primary endpoint

The primary endpoint is a hierarchical criterion assessed at day 28 and includes all-cause mortality followed by the time to clinical improvement. It is calculated in such a manner that death constitutes a worse outcome than delay of clinical improvement.

The time (days) to clinical improvement is defined as the time from randomisation to an improvement of at least two points (from the status at randomisation), using a seven-category ordinal scale derived from the WHO recommended instrument,[12] as proposed by Coa *et al*[16] (table 1). Since all included patients will at least require oxygen supplementation, live discharge from hospital will represent in itself a 2-point decrease in the 7-point scale, that is, clinical improvement.

Secondary endpoints

Secondary endpoints will include the following:

- Efficacy on morbi-mortality and organ function
  - Individual components of the hierarchical primary endpoint, including time to clinical improvement and all-cause death at day 28.
  - All-cause death at day 90.

Table 1 Seven-category ordinal scale derived from the who recommended instrument (proposed by Coa *et al*[16])

Status of patient	Description	Points
Not hospitalised	Resumption of normal activities	1
	Unable to resume normal activities	2
Hospitalised	Not requiring supplemental oxygen	3
	Requiring supplemental oxygen	4
Intensive care unit	Requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation or both	5
	Requiring invasive mechanical ventilation, Extracorporeal membrane oxygenation (ECMO) or both	6
Death	Death	7

Table 2 Sepsis-induced coagulopathy score[25]

Variable		Points
INR	≤1.2	0
	>1.2 to 1.4	1
	>1.4	2
Platelet count, $\times 10^9$ /L	≥150	0
	100 to <150	1
	<100	2
Total SOFA score*	0	0
	1	1
	≥2	2

*Summation of the SOFA respiratory, cardiovascular, hepatic and renal score components.
INR, International Normal Ratio; SOFA, Sequential Organ Failure Dysfunction.

  - Score on WHO ordinal scale and 7-point ordinal scale at day 28.
  - D-dimers and Sepsis-Induced Coagulopathy Score (see detailed definition in table 2) at day 7.
  - Percentage of patients needing invasive mechanical ventilation at day 28.
  - Number of days alive and supplemental oxygen-free at day 28.
  - Number of days alive and mechanical ventilator-free at day 28.
  - Number of days alive and vasopressor-free at day 28.
  - Length of ICU stay at day 28 and day 90.
  - Length of hospital stay at day 28 and day 90.
  - Quality of life assessed using a quality-of-life questionnaire (EuroQol 5-Dimension 5-Level, EQ-5D-5L)[17] at day 90.
- Efficacy on thrombotic events: percentage of patients with at least one thrombotic event at day 28, including ischaemic stroke, non-cerebrovascular arterial thrombotic event, deep venous thrombosis, pulmonary embolism or central venous catheter-related deep venous thrombosis.
- Tolerance to anticoagulation
  - Percentage of patients with at least one MBE at day 28, according to the ISTH definition.
  - Percentage of patients with at least one life-threatening bleeding event at day 28 according to the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) definition.
  - Percentage of patients with any bleeding event, whether major or minor, at day 28, with minor bleedings being all non-MBE.
  - Percentage of patients with HIT at day 28.

Classification of the severity of thrombotic and bleeding events will be carried out by an independent adjudication committee.

Sample size and its statistical justification

The required number of participants to be randomised is 300 patients (from 353 included). Estimates, derived from prior studies led in similar populations,[16] showed that a sample of at least 300 patients (100 per group) suffices to achieve ≥80% power that is required to detect a statistically significant difference in the ranked composite primary endpoint. The analyses rely on two-sided alpha of 0.017 using Bonferroni correction for multiple testing considering three pairwise comparisons between the randomised arms. Sample size calculation assumed having day 28 mortality of 24%, 21% and 18%, and time to clinical improvement of 16±3 days (SD), 14±3 days and 12±3 days, with LD-PA, HD-PA and TA, respectively. We hypothesise that the rate of positive CTPA would be 15%.[18 19] For such, we aim to include 353 patients in order to randomise 300.

Sample size calculation also considered the pairwise comparisons between the groups. For each performed comparison, 5000 samples were simulated using R software. For the first component of the hierarchical primary endpoint (mortality), survival curves were simulated based on a Weibull distribution using the R package simsurv. For the second component of the hierarchical primary endpoint (time to clinical improvement) assessed in alive patients, two different approaches, taking into account the distribution of this parameter, were used to test the robustness of results in relation with the retained hypotheses. First, a normal distribution was hypothesised with means±SD of 16±3, 14±3 and 12±3 days in LD-PA, HD-PA and TA, respectively. Second, incidence curves of clinical improvement were simulated based on Weibull distribution using the R package simsurv, with survival medians of 16, 14 and 12 days in LD-PA, HD-PA and TA groups, respectively. With both approaches, 5% of patients were systematically identified through simulation as alive patients at day 28 but without achieving clinical improvement, which is consistent with Cao et al.[16] SD and mean number of days to clinical improvement, as well as shape and scale parameters of Weibull survival curves simulations were determined from the study of Cao et al.[16] considering median (IQR) survival time and Kaplan-Meier curves. Within each sample/pairwise comparison, an individual score is calculated by comparing each patient in one group with all patients in the second group (23). These scores are then compared between groups using Mann-Whitney/Wilcoxon test in each of the 5000 samples, and the p value of each test is recorded. For each pairwise comparison, the percentage of tests with a $p<0.017$ is calculated, which gives an estimate of the achieved statistical power.

Recruitment

The expected duration of patients enrolment is 18 months starting from April 2021. The chronogram of the study is as follows: (1) December 2020: winning industrial grant award; (2) December 2020: promotion by Assistance Publique-Hôpitaux de Paris (AP-HP); (3) March

2021: approval by an independent ethics committee; (4) April 2021–October 2022: inclusion of patients; (5) 2022–2023: end of inclusions, monitoring by the participating centres and research work by the investigators; cleaning and closure of the database; blind review to screen for protocol violation, to define intention-to-treat (ITT) and per-protocol (PP) analysis populations; (6) 2022–2023: data analysis, writing the manuscript and submission for publication.

Allocation of intervention and data management

After signing the consent by the patient or their relative, all inclusion/exclusion criteria will be checked by the investigator before randomisation. Centralised blocked randomisation on the basis of a 1:1:1 ratio will be prepared by the Clinical Research Unit before the start of the trial. Randomisation will be carried out in balanced blocks and stratified by hospital centre and according to the following criteria at inclusion: need for intubation (yes or no), D-dimer levels (more or less than 3 µg/mL) and body mass index (more or less than 30 kg/m^2). Patients will be randomised electronically on logging to the centralised electronic case report form (e-CRF) website 'Cleanweb' provided by Telemedicine technologies.

Non-identifying data will be entered into the e-CRF via a web browser by a trained investigator or research assistant at each centre. The participating centres have access to e-CRF forms via a web-based data collection system (unique identification and password by user). Patients' follow-up and work schedule are detailed in the study Gantt chart (table 3). The e-CRF was devised by the principal investigator and the scientific supervisor of the study in collaboration with the data manager of the clinical research unit, Henri Mondor Hospital AP-HP. CRF and data dictionary (containing variables coding and definitions) are saved and archived in the clinical research unit—Henri Mondor secured servers. Paper CRF are available in the documentation provided at each site. eCRF (CleanWeb Telemedecine) uses the secured computer servers of AP-HP. The computer files used for this research are implemented in compliance with the French (amended 'Informatique et Libertés' law governing data protection) and European (General Data Protection Regulation, GDPR) regulations. The sponsor already obtained authorisation of CNIL (French Data Protection Agency) before implementing any data processing involving data required for this research (Ref.:MLD/MFI/AR215255 AUTORISATION). Database quality control is undertaken by Data manager of the clinical research unit—Henri Mondor Hospital, AP-HP (missing data, range checks on quantitative values, date chronology check; R-Project computer programming) and put at the disposal of the investigation team. Data management procedures are validated by the clinical research nit quality specialist and recorded in their secured servers and on paper.

Table 3 Study Gantt chart (work schedule)

Procedures and assessments (C=care; R=research)	Day 0 (inclusion)	Day 1 (randomisation)	Day 7	Day 2–14	Day 15–28 (or hospital discharge)	Day 90 ±10 days (end of study)
Inclusion and non-inclusion criteria	R					
Enrolment						
Informed consent	R					
CTPA		C				
Intervention						
Low-dose prophylactic anticoagulation strategy		C		C		
High-dose prophylactic anticoagulation strategy		C		C		
Therapeutic anticoagulation		C		C		
Assessments						
Characteristics of the patient*	C					
Seven-category ordinal scale and its components†		C		C	C	
D-dimers and platelet count		C	C	C		
Sepsis coagulopathy score and its components‡		C	C			
Adverse event		C		C	C	R
ICU stay and hospital stay					R	R
Vital status		C		C	C	R

*Characteristics of patients include age, gender, height, weight, severity score indicated by the Simplified Acute Physiological Score II and the Sepsis-related Organ Failure Assessment score, pre-existing conditions (chronic cardiovascular, respiratory, renal, liver or gastric diseases, arterial hypertension, diabetes mellitus, thrombotic or bleeding event, stroke, neoplasia, positive serology for HIV, solid-organ transplantation), treatments of COVID-19 at baseline, baseline organ support.
†Derived from the WHO scale.[12]
‡International normal ratio, platelet count, Sepsis-related Organ Failure Assessment score.[25]
CTPA, CT with pulmonary angiogram; ICU, intensive care unit.

Statistical methods

All analyses will be performed by the study statistician according to a predefined statistical analysis plan, using Stata V.16.1 (StataCorp) and R V.4.0.3 (R Foundation for Statistical Computing, Vienna, Austria). A two-tailed $p<0.05$ should indicate statistical significance.

In compliance with the SPIRIT statement, a flow diagram will describe the progress of the three groups of patients throughout the different phases of the trial (enrolment, allocation, received interventional agents, follow-up and data analysis). The analysis will be performed on an ITT basis. In case of premature interruption or withdrawal from the study, patients will not be substituted. Missing values will be described and, according to their nature and frequency, multiple imputation methods will be applied. A PP analysis will be conducted as the trial sensitivity analysis since it excludes patients wrongly randomised or who did not receive the allocated intervention.

Comparative analysis will systematically be done with (main analysis) and without adjustment for randomisation stratification factors. There is no intention to perform interim analysis. The primary endpoint analysis will be done on the ITT population whereas supportive analyses on the PP population. The latter aim is to investigate PP-excluded patients and their impact on ITT analysis, and eventually to check whether similar results can be obtained for a robust interpretation. All secondary endpoints analyses will be conducted on both ITT and PP populations to assess the robustness of the results.

Descriptive analysis

Descriptive statistical analyses will be conducted on the whole study population, in particular the randomised groups to describe their general and baseline characteristics, demographics, history, as well as numbers of premature study withdrawals. Quantitative variables will be presented as mean (±SD) or median (25–75th percentiles) according to the normality of their distribution as assessed by Shapiro-Wilk tests and graphical methods. Qualitative variables will be presented as numbers (%).

Analysis of the primary endpoint

The prespecified primary endpoint will be a ranked composite score that incorporates death and time to clinical improvement, calculated in such a manner that death constitutes a worse outcome than delayed clinical improvement. Each patient will be compared with every other patient in the study and assigned a score (equality: 0, win:+1, loss: −1) for each pairwise comparison based on who fared better. If a patient survived and the other did not, the first will be attributed +1 and the latter −1 for that pairwise comparison. If both patients in the pairwise comparison survived, the scoring will depend on who needed more time (days) to clinically improve: fewer days mean a score of +1, and more days mean a score of −1. If both patients survived and had the same number of days to clinical improvement, or if both patients died, both will score 0 for that pairwise comparison. For each patient, scores of all pairwise comparisons will be summed to obtain a cumulative score. These cumulative scores will be ranked and compared between the three groups via non-parametric Mann-Whitney test.

Analysis of secondary endpoints

Comparisons between randomised groups at given timepoints will be conducted using χ^2 or Fisher exact tests, according to expected numbers in crossings, for categorical variables, and using t-test or non-parametric Mann-Whitney test (pairwise comparisons), and analysis of variance or Kruskal-Wallis tests (comparisons of >2 groups) for quantitative variables, as appropriate. Pairwise comparisons within groups (across timepoints) will be conducted using tests for paired data, that is, McNemar test for qualitative data, and t-tests for paired data or Wilcoxon signed ranks for continuous data, as appropriate.

Individual components of the composite primary endpoint will be assessed as secondary endpoints, and those include all-cause mortality at day 28 and number of days to clinical improvement. For such, calculation of time-to-event endpoints based on follow-up censored data will be employed, taking into account the competing risks of hospital discharge (for mortality evaluation) and death (for time to clinical improvement). Kaplan-Meier survival curves and cumulative incidence curves will be plotted for each treatment group, and Fine-Gray regression model will be used to calculate sub-HRs along with their 95% CIs and corresponding p values.

Analyses of independent determinants of quantitative secondary endpoints will be performed using multivariable linear regression model adjusting for baseline characteristics. As for global longitudinal analysis, we will use generalised linear regression mixed model to test interactions between timepoints, groups and prespecified predictors while entering patient level as a random effect to take into consideration the hierarchical structure of repeated data.

Tolerance analysis will examine the intervention-related adverse events, according to their period of appearance and the concerned randomised group, to compare rates and time of occurrence.

Data monitoring

The trial steering committee (principal investigator, senior investigator and methodologist) will supervise the progression and monitoring of the study. Research assistants will regularly monitor all centres on site to check protocol adherence and accuracy of the recorded data. An investigator at each centre will be responsible for daily patient screening, patient enrolment, adherence to protocol and completion of the eCRF. Since the three treatment strategies are currently used in routine practice, no data safety monitoring board was required by the ethical committee.

Patient and public involvement

Patients and/or the public were not involved in the development of this study.

ETHICS AND DISSEMINATION

Ethical approval

The study has been approved by an independent ethics committee (Ethics Committee, Ile de France VII, Paris, France) under the registration number 2020-A03531-38.

Consent to participate

Patients will be included after signing a written informed consent (online supplemental appendix B). If the patient is not able to understand the information given in the consent, they can be included if a next of kin consents or helps obtain the consent. Eligible patients unable to receive information and for whom a substitute decision-maker is not present, can still be included through a process of deferred consent. After recovery, the patient's agreement to stay in the trial will be sought.

Confidentiality

Data will be handled according to the French law on data protection and the European GDPR. All original records will be archived at the trial sites for 15 years.

Funding and sponsorship

This study was funded by a grant from LEO Pharma. The sponsor is AP-HP (Délégation à la Recherche Clinique et à l'Innovation).

Access to data

Investigators will make the documents and individual data required for monitoring, quality control and audit of the study available to dedicated persons, in fulfilment with the law.

Dissemination policy

Findings will be published in peer-reviewed journals and presented at national and international meetings. Communications, reports and publication of the results of the study will be placed under the responsibility of the principal investigator–coordinator of the study and the steering committee. Reporting will adhere to the SPIRIT statement, and rules of publication will follow the international recommendations as for The Uniform Requirements for Manuscripts (ICMJE, April 2010) (SPIRIT checklist, online supplemental appendix C).

DISCUSSION

Currently, there are no randomised controlled trials investigating the best anticoagulation strategy to manage microvascular thrombosis and to hinder the evolution of lung and multiorgan microcirculatory dysfunction in patients with COVID-19 without initial macrovascular thrombosis.

Recent trials have studied various anticoagulation strategies using heparin in COVID-19 patients.[8] In the Iranian INSPIRATION trial,[20] Sadeghipour *et al* compared the efficacy of standard LD-PA (40 mg enoxaparin once a day) with weight-based, higher dose-PA (1 mg/kg enoxaparin) in severe COVID-19 patients admitted to ICU. Higher dose-PA did not result in a significant difference in the primary outcome (a composite of adjudicated venous or arterial thrombosis, indication for extracorporeal membrane oxygenation, or mortality within 30 days), as compared with the standard-dose PA. Additionally, the risk of bleeding was similar between the two groups. An international, multiplatform, randomised clinical trial combined data from patients who had already been enrolled in a conventional randomised trial (ACTIV-4a) and in two response-adaptive randomisation trials (REMAP-CAP and ATTACC). They found that the potential benefits and risks of TA versus standard PA (at a lower or higher dose based on local practice) depended on the initial severity of patients.[21 22] In critically ill patients, TA did not improve the primary outcome of organ support–free days at day 21 and was associated with more major bleedings (3.8% vs 2.3%) as compared with PA.[22] In non-critically ill patients, TA appeared to increase the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support. However, major bleeding occurred in 1.9% of the patients receiving TA and in 0.9% of those receiving PA.[21]

Our ANTICOVID study differs from these studies in several methodological and clinical aspects. The inclusion criteria differ as CTPA is systematically (ANTICOVID) vs non-systematically (INSPIRATION, REMAPCAP, ACTIV-4, ATTACC) performed to exclude macrothrombosis, which is de facto an indication for curative anticoagulation. By excluding macrothrombosis before randomisation, ANTICOVID will provide an answer to the specific question of microthrombosis. On the other hand, and in contrast to other trials, ANTICOVID explicitly excludes patients with renal failure (creatinine clearance <30 mL/min), which has been entangled as an independent risk factor for bleeding in critically ill patients requiring TA.[23] Additionally, ANTICOVID excludes patients attaining the extremes of body weights, for whom LMWH dosage has not been assessed. In particular, obese patients, since they have a lower proportion of lean body mass in relation to their big total body weight. As a result, determining LMWH dosage based on total body weight could cause supra-therapeutic anticoagulation.[24] ANTICOVID will allow evaluation of anticoagulation dose escalation in a population with a minimal baseline bleeding risk. Eventually, our study is the only one to investigate in separate arms, lower and higher prophylactic doses, and compare them with curative anticoagulation. For all of the above, ANTICOVID trial is needed in order to explore the lowest effective dose (given the bleeding risk of anticoagulation) and to answer the key question of dose escalation anticoagulation in COVID-19 patients without initial macrovascular thrombosis.

Our study has several limitations. Anticoagulation assignment was open-label given the overburdened, resource-limited healthcare system during the pandemic. Time to clinical improvement, the second component of the hierarchical primary endpoint, may be too subjective, thus liable to performance bias. Detection bias could occur if potential events (especially incidental thromboses) were less likely to be investigated in patients receiving TA than in those receiving LD-PA or HD-PA. The opposite could be true for bleeding events. Reporting bias is unlikely for the primary outcome given that (1) all cause death is objective and (2) ICU hospitalisation and type of ventilatory support determining time to clinical improvement are unambiguously supported by medical records. Nonetheless, an independent clinical events committee will blindly adjudicate all relevant outcomes. Both ICU and non-ICU patients are eligible, so our future results should not be compared directly to those of other trials limited only to critically ill patients or to non-ICU patients. We will not include obese patients and patients with renal failure, which limits the generalisability of the results to all COVID-19 inpatients. Finally, we will not take into account symptoms duration in the analysis neither quantify microvascular thrombosis on CTPA.

In summary, ANTICOVID trial is an open label randomised controlled trial testing the efficacy of three routinely used anticoagulation strategies (LD-PA, HD-PA and TA) in limiting the extension of microvascular thrombosis in severe COVID-19 patients without initial macrovascular thrombosis. The trial targets a well-selected population (notably at lower risk of bleeding), with a suitable primary objective and experimental design, to provide a robust response (lowest effective dose with respect to the bleeding risk of anticoagulation). Therefore, this trial may help establish international recommendations with a high level of evidence for the efficacy and safety of anticoagulation dose escalation needed to improve outcomes in severe COVID-19 patients.

Author affiliations
[1]Service de Médecine Intensive Réanimation, Hôpital Tenon, Département Médico-Universitaire APPROCHES, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France
[2]Université Paris Est, Groupe de Recherche Clinique GR05 CARMAS, Institut Mondor de recherche biomédicale, INSERM, Créteil, France
[3]Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, Argenteuil, France
[4]Department of Intensive Care, Hôpital Raymond Poincaré, Assistance Publique - Hopitaux de Paris, University Versailles Saint Quentin - University Paris Saclay, Garches, France
[5]Laboratory of Infection & Inflammation - U1173, School of Medicine Simone Veil, University Versailles Saint Quentin - University Paris Saclay, INSERM, Garches, France
[6]Service de Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, INSERM UMRS-1144, Université de Paris, Paris, France
[7]Service de Médecine Intensive Réanimation, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France
[8]Service de Médecine Intensive Réanimation, Centre Hospitalo-Universitaire de Poitiers, INSERM CIC 1402 (ALIVE group), Université de Poitiers, Poitiers, France
[9]Service d'Anesthésie-Réanimation polyvalente, Hôpital Saint Camille, Bry-sur-Marne, France
[10]Service de Médecine Intensive Réanimation, Hôpital Simone Veil, Centre Hospitalier de Cannes, Cannes, France
[11]Unité INSERM 1065, Laboratoire C3M, Université Côte d'Azur, Nice, France
[12]Service de Réanimation Polyvalente, Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France
[13]Service de Médecine Intensive Réanimation, Centre Hospitalier Léon Binet, Provins, France
[14]Service de Médecine Intensive Réanimation, Hôpital l'Archet 1, Centre Hospitalier Universitaire de Nice, Nice, France
[15]UR2CA Unité de Recherche Clinique Côte d'Azur, Université Côte d'Azur, Nice, France
[16]Département de Médecine intensive, Groupe Hospitalier Sud Ile de France, Melun, France
[17]Service de Réanimation, INSERM, Institut Pasteur de Lille, U1167, Université de Lille, Centre Hospitalo-Universitaire Lille, Lille, France
[18]Service de Pneumologie et de soins intensifs Respiratoires, Hôpital Larrey, Toulouse, France
[19]Service de Médecine Intensive Réanimation, Centre Hospitalo-Universitaire Gabriel-Montpied, Clermont-Ferrand, France
[20]Service de Médecine Intensive Réanimation, Hôpital Louis-Mourier, DMU ESPRIT, Assistance Publique-Hôpitaux de Paris, Colombes, France
[21]Université de Paris, UFR de médecine Paris Nord, Paris, France
[22]Service de Médecine Intensive Réanimation, Centre Hospitalier La Dracenie De Draguignan, Draguignan, France
[23]Service de Médecine intensive Réanimation, Hôpital Pitie Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France
[24]Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Université Sorbonne Paris Nord, Bobigny, France
[25]Service de Médecine Intensive Réanimation, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
[26]Medical and infectious diseases ICU (MI2), Bichat Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, IAME, INSERM U1137, Paris, France
[27]Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Département Médico-Universitaire Médecine, Assistance Publique-Hôpitaux de Paris, Créteil, France
[28]Unité de Recherche Clinique Henri Mondor, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Assistance Publique-Hôpitaux de Paris, Créteil, France

Twitter Alexandre Robert @AlexRobert84 and Denis Doyen @Denis_Doyen

Acknowledgements The authors thank Professor Nadia Aissaoui, MD.PhD (Department of Intensive Care, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France), and Professor Matthieu Schmidt, MD.PhD (Department of Intensive Care, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France) for being part of the independent endpoint adjudication committee. We thank Yasmina Moussaoui (Unité de Recherche Clinique Henri Mondor, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, AP-HP, Créteil, France) for her valuable work.

Contributors VL and AMD in collaboration with all authors designed the study and wrote the manuscript together. EA provided substantial contributions to the conception and design of the study, and wrote the statistical analysis plan and estimated the sample size. VL, DC, NH, BM, HA-O; FB, SC, AR, EV, MF, DD, MM, SP, EN-S, BS, NZ, S-AP, MD, WJ, EM, J-FT, MT, KR, SG, SB, GV, MF, EA and AMD contributed for drafting the work, revising it critically for important intellectual content and approved the final version of the manuscript. VL, DC, NH, BM, HA-O; FB, SC, AR, EV, MF, DD, MM, SP, EN-S, BS, NZ, S-AP, MD, WJ, EM, J-FT, MT, KR, SG, SB, GV, MF, EA and AMD gave their agreement to be accountable for all aspects of the work, and ensure the accuracy and integrity of any part of it.

Funding This study was funded by a grant from LEO Pharma. The sponsor is Assistance Publique—Hôpitaux de Paris, AP-HP (Délégation à la Recherche Clinique et à l'Innovation, DRCI).

Competing interests AMD reports lectures for Leo Pharma. EA reports personal fees from GBT, personal fees from Hemanext, both unrelated to the present study. GV received research grant from Bio-Mérieux, SOS Oxygène, Janssen, all unrelated to the present study; and advisory board fees from BioMérieux that are unrelated to the present study. VL receives advisory board fees from Amomed, unrelated to the present study.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iDs
Vincent Labbe http://orcid.org/0000-0002-6334-4324
Martin Dres http://orcid.org/0000-0001-9191-6089
Guillaume Voiriot http://orcid.org/0000-0003-2236-0288
Armand Mekontso Dessap http://orcid.org/0000-0001-5961-5577

REFERENCES

1 Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood* 2020;135:2033–40.
2 Zhang Y, Xiao M, Zhang S, *et al*. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. *N Engl J Med* 2020;382:e38.
3 Danzi GB, Loffi M, Galeazzi G, *et al*. Acute pulmonary embolism and COVID-19 pneumonia: a random association? *Eur Heart J* 2020;41:41.
4 Al-Samkari H, Karp Leaf RS, Dzik WH, *et al*. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood* 2020;136:489–500.
5 Susen S, Tacquard CA, Godon A. Propositions Du GFHT/GIHP pour Le traitement anticoagulant pour La Prévention du Risque thrombotique CheZ un patient hospitalisé avec COVID-19 2020.
6 Bikdeli B, Madhavan MV, Jimenez D, *et al*. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. *J Am Coll Cardiol* 2020;75:2950–73.
7 Susen S, Tacquard CA, Godon A, *et al*. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. *Crit Care* 2020;24:364.
8 Recommandations d'experts portant sur la prise en charge en réanimation des patients infectés SARS-CoV2. SRLF-SFAR -GFRUP-SPILF-SPLF.. *Mise en oeuvre avec la mission COREB nationale* 2020.
9 Maiese A, Manetti AC, La Russa R. Autopsy findings in COVID-19-related deaths: a literature review. *Forensic Sci Med Pathol*. [Epub ahead of print: 7 October 2020]. doi:10.1007/s12024-020-00310-8
10 Varga Z, Flammer AJ, Steiger P, *et al*. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet* 2020;395:1417–8.
11 Ackermann M, Verleden SE, Kuehnel M, *et al*. Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med* 2020;383:120–8.
12 WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020;20:e192–7.
13 Konstantinides SV, Meyer G, Becattini C. Esc guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of cardiology (ESC). *Eur Respir J* 2019;2019:54.
14 Laurence N, Cronan John J, Lilly Michael P. Ultrasound for lower extremity deep venous thrombosis. *Circulation* 2018;137:1505–15.
15 Keyt H. WHO recommends corticosteroids for patients with severe or critical COVID-19. *Ann Intern Med* 2021;174:JC2.
16 Cao B, Wang Y, Wen D, *et al*. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med* 2020;382:1787–99.
17 Brooks R. EuroQol: the current state of play. *Health Policy* 1996;37:53–72.
18 COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. *Intensive Care Med*. [Epub ahead of print: 29 October 2020]. doi:10.1007/s00134-020-06294-x
19 Suh YJ, Hong H, Ohana M. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. *Radiology* 2020:203557.
20 INSPIRATION Investigators. Effect of Intermediate-Dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit. *JAMA*. [Epub ahead of print: 18 March 2021]. doi:10.1001/jama.2021.4152
21 ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, *et al*. Therapeutic anticoagulation with heparin in Noncritically ill patients with Covid-19. *N Engl J Med* 2021;385:790–802. doi:10.1056/NEJMoa2105911
22 REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, *et al*. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. *N Engl J Med* 2021;385:777–89. doi:10.1056/NEJMoa2103417
23 Brown RB, Klar J, Teres D, *et al*. Prospective study of clinical bleeding in intensive care unit patients. *Crit Care Med* 1988;16:1171–6.
24 Clark NP. Low-Molecular-Weight heparin use in the obese, elderly, and in renal insufficiency. *Thromb Res* 2008;123 Suppl 1:S58–61.
25 Iba T, Nisio MD, Levy JH, *et al*. New criteria for sepsis-induced coagulopathy (sic) following the revised sepsis definition: a retrospective analysis of a nationwide survey. *BMJ Open* 2017;7:e017046.

APPENDICE A: list of study sites

Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France

Service de Maladies Infectieuses et Tropicales, Hôpital Tenon, Paris, France

Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, Argenteuil, France.

Service de Médecine Intensive Réanimation, Hôpital Raymond Poincaré, Garches, France.

Service de Maladies Infectieuses et Tropicales, Hôpital Raymond Poincaré, Garches, France.

Service de Réanimation Médicale et Toxicologique, Hôpital Lariboisière, Paris, France

Service de Médecine Intensive Réanimation, Hôpital Saint Antoine, Paris, France

Service de Maladies Infectieuses et Tropicales, Hôpital Saint Antoine, Paris, France.

Service de Médecine Intensive Réanimation, Centre Hospitalo-Universitaire de Poitiers, Poitiers, France.

Service d'Anesthésie-Réanimation polyvalente, Hôpital Saint Camille, Bry-sur-Marne, France

Service de Maladies Infectieuses et Tropicales, Hôpital Saint Camille, Bry-sur-Marne, France

Service de Médecine Intensive Réanimation, Hôpital Simone Veil, Centre Hospitalier de Cannes, Cannes, France

Service de Réanimation Polyvalente, Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France.

Service de Médecine Intensive Réanimation, Centre Hospitalier Léon Binet, Provins, France

Service de Médecine Intensive Réanimation, Hôpital l'Archet 1, Centre Hospitalier Universitaire de Nice, Nice, France.

Service de Maladies Infectieuses et Tropicales. Hôpital l'Archet 1, Centre Hospitalier Universitaire de Nice, Nice, France.

Département de Médecine intensive, Groupe Hospitalier Sud Ile de France, Melun, France.

Service de Réanimation, Centre Hospitalo-Universitaire Lille, Lille, France

Service de pneumologie et de soins intensifs respiratoires, Hôpital Larrey, Toulouse, France

Service de Médecine Intensive Réanimation, Centre Hospitalo-Universitaire Gabriel-Montpied, Clermont-Ferrand, France.

Service de Médecine Intensive Réanimation, Hôpital Louis Mourier, Colombes, France.

Service de Médecine Intensive Réanimation, Centre Hospitalier La Dracenie De Draguignan, Draguignan, France

Service de Médecine intensive Réanimation, Hôpital Pitie Salpêtrière, Paris, France

Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Bobigny, France

Service de Maladies Infectieuses et Tropicales, Hôpital Avicenne, Bobigny, France

Service de Médecine Intensive-Réanimation, Hôpital Saint-Louis, Paris, France

Service de Médecine Intensive et Réanimation Infectieuse, Hôpital Bichat, Paris, France

Service de Médecine Intensive-Réanimation, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France

Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Créteil, France

Service du Département d'Aval des Urgences, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Créteil, France

Service de Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Henri Mondor-Albert Chenevier, Créteil, France

Title of the research:
Anticoagulation in Patients with Severe COVID-19: a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial
(ANTICOVID)

This research is promoted by *Assistance Publique - Hôpitaux de Paris*
Represented by the Director of
***Direction de la Recherche Clinique et de l'Innovation* (DRCI)**
1 avenue Claude Vellefaux
75010 Paris

PARTICIPATION INVITATION

Dear Madam, dear Sir

Dr./Pr. (delete as appropriate)..... (First name, Surname), working at ……. Hospital, invites you to participate in a research study conducted to examine your disease.
We highly encourage you to read this document carefully before making any decision. Do not hesitate to ask for further information.
If you agree to participate in this research, you will be asked to sign a written consent.

1) What is the objective of this research?

You are admitted to hospital to be treated for COVID-19. The study you are asked to take part in assesses the different approaches used to prevent blood clotting (anticoagulation) in patients with COVID-19, either with high dose (therapeutic), low dose (standard prophylactic) or intermediate dose (intermediate prophylactic) anticoagulation. The three options are currently employed in the management of COVID-19.
To perform this research study, we intend to include 353 of the COVID-19 patients who are admitted to French hospitals.

2) What does the research consist in?

COVID-19 may trigger excessive coagulation leading to the development of blood clots in the lung vessels (pulmonary thrombosis). Some middle and big-size clots can be seen via an imaging technique called chest Computed Tomography with Pulmonary Angiogram (CTPA), but not the small clots.
If you agree to participate in this study, we will do CTPA since it is a standard investigation tool to look for pulmonary thrombosis in COVID-19 patients.
If your CTPA is positive, you will receive anticoagulant treatment at a therapeutic dose for three months, as recommended.
If your CTPA is negative, you will receive anticoagulant treatment, either at standard prophylactic (low) dose, intermediate prophylactic (intermediate) dose, or therapeutic (high) dose. The anticoagulant dose will be randomly selected (this random selection is called randomization). Except in particular conditions, the anticoagulant is tinzaparin, of which you will take one subcutaneous injection a day for 14 days.
In all cases, you will also receive the recommended treatment for COVID-19 throughout your hospitalization.

3) What is the work schedule of the research?

The research is expected to take 6 months and your participation 90 days (3 months). After signing your consent form at the first visit, your participation in the study will start. If you did not undergo CTPA within the three days prior to inclusion, new CTPA would be performed within 24 hours of your inclusion in this study. If your CTPA is negative for thrombosis, the dose of anticoagulant therapy will be randomized within 24 hours of CTPA. This randomization is performed at the first day of the study (D1).

You will receive the randomized strategy for 14 days, from D1 to D14. Your monitoring data (routine clinical examinations and blood tests) will be daily collected during your hospitalization. For a better assessment of your health status, your follow-up in this study will take three months. The evolution of your condition (vital status, oxygen support, and other complications) will be evaluated at D28 (or at discharge if it occurs before D28). You will receive a telephone call at month 3 of follow up to assess your quality of life. The follow-up will be identical for all patients included in the study, whether randomized or not.

4) What are the benefits of your participation?

By participating in this research, you will benefit from regular medical follow-up at no additional cost. Intermediate prophylactic and therapeutic anticoagulation strategies could decrease the duration of COVID-19 as well as its mortality. In addition, your participation will help us deepen our knowledge about COVID-19 treatment.

5) What are the anticipated risks and constraints added by the research?

Anticoagulation can induce bleeding (major bleeding is exceptional). The study approaches are already part of the routine medical treatment of COVID-19 patients. Therefore, there is no risk specifically related to this research. Close monitoring, as is the standard protocol in patients hospitalized for COVID-19, will be performed during hospitalization.
If you agree to participate, you should respect the following point: not to participate in another research project without your doctor's approval, in order to protect yourself from any health problems that could result, for example, from possible incompatibilities between the studied drugs or from other exposures.

6) What are the potential medical alternatives?

If you choose not to participate in this research, you will receive appropriate healthcare according to your condition, in compliance with standard clinical practice.

7) What kind of medical care to have after participation?

The follow-up is not specific for this study. You will continue to receive the care adapted to your health condition whether it concerns the usual management in case of premature interruption of the research or the care to receive at the end of your participation.
Your doctor may decide at any time to stop your participation and should explain the reasons to you.

8) If you participate, how will your collected data be used in the research?

Within the framework of the research you are invited to participate in, the treatment of your personal data will be carried out by AP-HP, the research promoter in charge of data management, to analyze the results.

This data processing is necessary to carry out research of public health interest, which comes in alignment with the missions of AP-HP as a public university hospital.

For this purpose, your medical and lifestyle data will be transmitted to the Promoter or to persons or partners working on its behalf, in France or abroad. Such data will be identified by a registration number. As well, such data could be transmitted to French or foreign health authorities, under conditions that guarantee their confidentiality.

It is also possible that your medical data, which could be documented in reports by competent authorities interested in the strategies evaluated in this research, be transmitted to an industrial company in order to allow a greater number of patients to benefit from the results of this research. This transmission will be done under conditions that guarantee confidentiality.

Your data could be used in further research work or complementary analysis in collaboration with private or public partners, in France or abroad, under conditions that guarantee their confidentiality and the same level of protection as stated by the European legislation.
You can object to any further analysis of your data at any time by informing the doctor who is following you in this research.

Your data will only be kept for as long as is strictly necessary and warranted by the research purpose. It will be stored in the information systems of the data manager for two years after the last publication of the research results. Your data will then be archived in fulfilment with the regulations in force.

The database used in this research is established in compliance with the French (modified "*Informatique et Libertés*" law) and European (*Règlement Général sur la Protection des Données* - RGPD) laws. You have the right to access, modify, restrict, and object to the processing of data which are covered by professional secrecy and used in the framework of this research.

If you decide to stop your participation, the data collected prior to this decision will be used in accordance with the regulations and exclusively for the purposes of this research. Deleting them would compromise the validity of the research results. However, from that date on your data will not be further used in this research or in other works.

If you have a problem concerning your rights, you can contact the AP-HP's data protection officer at the following address: protection.donnees.dsi@aphp.fr, who will be able to explain to you the possible channels available for you at the CNIL. You can also use your right to complain directly to the CNIL (for further information on this subject, visit www.cnil.fr).

9) How is this research supervised?

AP-HP has taken all the measures to carry out this research in compliance with the Public Health Regulations applicable to research involving human volunteers.

AP-HP has taken out an insurance policy (number …….) that guarantees its civil liability and that of all those involved with HDI-GERLING company through its insurance broker BIOMEDICINSURE whose address is *Parc d'Innovation, Bretagne Sud C.P.142 56038 Vannes Cedex*.

AP-HP obtained approval from the ethics committee [indicate the name of the CPP] on [indicate the date of the meeting in dd/mm/yyyy format].

10) What are your rights?

Your participation in this research is free and voluntary. Your decision will not compromise the quality of care and treatment you are expected to receive.

Throughout the study period and at any given time, you can ask your investigating doctor for further information about your health as well as explanations of the research process.

You may withdraw from the research at any time without explanation, without any consequences for your treatment or the quality of care you receive, and without any consequences for your relationship with your doctor. After this withdrawal, you may be followed by the same medical team. In this case, the data collected until the withdrawal will be used for the analysis of the research results.

Your medical file will remain confidential and can only be consulted under the responsibility of the doctor in charge of your treatment as well as by the health authorities and by persons who are authorised by AP-HP for research and are subjected to professional confidentiality.

At the end of the study and its data analysis, you can have access to the overall results by asking the doctor who is treating you in the study.

You can also access all your medical data directly or through a doctor of your choice in fulfillment with Article L 1111-7 of the Public Health Regulations.

If you agree to participate in the research after you have read all this information, discussed it with your doctor and had time to think about it, you will be asked to sign and date the informed consent form at the end of this document.

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

CONSENT FORM

I, the undersigned, Ms., Mr. [delete as appropriate] (First name, Surname) ..... voluntarily agree to participate in the study entitled

"Anticoagulation in Patients with Severe COVID-19: a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial"

promoted by *Assistance Publique - Hôpitaux de Paris* and I was informed about by Dr./Pr. (name, surname, telephone)....., investigator of this research.

- I have read the participation invitation version 1.0 of 18/12/2020 (3 pages), which explains the purpose of this trial, how it will be conducted, and what my participation will consist of;
- I will keep a copy of the participation invitation and the consent form:
- I have received appropriate answers to all my questions;
- I have had sufficient time to make my decision;
- I have understood that my participation is free and that I can stop my participation at any time, without any liability and without prejudices to the quality of care I will receive;
- I have been informed that the data collected in the research may be used for other studies, and that I can object to that at any time;
- I am aware that my participation can also be interrupted whenever necessary by the doctor who should then explain the reasons;
- I have been informed that my participation in this research will last three months during which I cannot consider participation in another research without informing the investigating doctor in charge of my case in this trial,
- My consent in no way releases the doctor who is following me in the research nor AP-HP from all their responsibilities, and I retain all rights guaranteed to me by the law.

Signature of the participating person		**Signature of the doctor**	
First name, Surname:		Fist name, Surname:	
Date:	Signature:	Date:	Signature:

This document must be produced in three copies: one copy must be kept by the investigator for 15 years, the second given to the consenting person, and the third sent to AP-HP in a sealed envelope at the end of the study.

SPIRIT
STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ItemNo	Description	Repored on page NO
Administrative information			**27-28-29**
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	27,28
Protocol version	3	Date and version identifier	27
Funding	4	Sources and types of financial, material, and other support	28
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,2,3,428
	5b	Name and contact information for the trial sponsor	28
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	n/a
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	12, 17, 28
Introduction			6

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	6
	6b	Explanation for choice of comparators	6
Objectives	7	Specific objectives or hypotheses	7
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	8,9
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9,10
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	10
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	n/a
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	10

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	11,12
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	11
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13,14
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	n/a
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	14
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	14
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	14
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a

	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11,14,15,17
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	11,17
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	14,15
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	15,16,17
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	15,16
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	15
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	17

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11,14,17
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	n/a
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	17,18
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	18
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	18
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	18
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a

Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	18
	31b	Authorship eligibility guidelines and any intended use of professional writers	18
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	22
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.